Results 1 to 10 of about 642,659 (199)

Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease

Journal of Clinical Medicine, 2021
Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein (LDL) cholesterol and cardiovascular event rates, yet due to their high price remain underutilized and difficult to prescribe in clinical practice.
Scott Keith, Drew Johnson, Joshua Banks   +2 more
exaly   +2 more sources

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats

Archives of Biochemistry and Biophysics, 2020
Nipon Chattipakorn, Wasana Pratchayasakul   +1 more
exaly  

A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove

Bioorganic and Medicinal Chemistry, 2020
Benny Evison, Herbert Treutlein, Jun Zeng   +2 more
exaly  

PCSK9 inhibitor and atorvastatin reduce cardiac impairment in ovariectomized prediabetic rats via improved mitochondrial function and Ca2+ regulation

Journal of Cellular and Molecular Medicine, 2020
Nipon Chattipakorn, Wasana Pratchayasakul, Busarin Arunsak   +2 more
exaly  

Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates

Journal of Clinical Lipidology, 2019
Leena Choi, Victoria Reynolds
exaly  

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

Circulation, 2018
Aaron Aday, Lynda Rose
exaly  

PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats

European Journal of Pharmacology, 2020
Nipon Chattipakorn, Wasana Pratchayasakul   +1 more
exaly  

What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?

Cardiovascular Research, 2019
P E Penson
exaly  

The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population

Clinical Therapeutics, 2022
exaly  

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association

Journal of Clinical Lipidology, 2017
Kevin Maki, Terry Jacobson, Dean G Karalis   +2 more
exaly